Pacific Biosciences of California, Inc.

NasdaqGS:PACB Stock Report

Market Cap: US$996.8m

Pacific Biosciences of California Past Earnings Performance

Past criteria checks 0/6

Pacific Biosciences of California's earnings have been declining at an average annual rate of -36.2%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 18.1% per year.

Key information

-36.2%

Earnings growth rate

-23.0%

EPS growth rate

Life Sciences Industry Growth21.5%
Revenue growth rate18.1%
Return on equity-43.7%
Net Margin-153.0%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership

Mar 19

Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth

Feb 08

With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

Feb 01
With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Dec 18
What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

Nov 13
Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Aug 28
The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Jul 31
Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Jul 06
Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

May 25
Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Mar 29
Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

Feb 26
Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

Time To Worry? Analysts Just Downgraded Their Pacific Biosciences of California, Inc. (NASDAQ:PACB) Outlook

Aug 08
Time To Worry? Analysts Just Downgraded Their Pacific Biosciences of California, Inc. (NASDAQ:PACB) Outlook

Pacific Biosciences: A Prime Candidate For My 'Bio Boom' Portfolio

Jul 27

Is Pacific Biosciences of California (NASDAQ:PACB) Using Debt Sensibly?

Jul 11
Is Pacific Biosciences of California (NASDAQ:PACB) Using Debt Sensibly?

Pacific Biosciences Hit By Sentiment, But The Future Of Long-Read Sequencing Is Strong

Apr 05

Is Pacific Biosciences of California (NASDAQ:PACB) Using Too Much Debt?

Feb 24
Is Pacific Biosciences of California (NASDAQ:PACB) Using Too Much Debt?

Revenue & Expenses Breakdown
Beta

How Pacific Biosciences of California makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:PACB Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 23201-307170187
30 Sep 23170-309169185
30 Jun 23146-319162185
31 Mar 23134-321161189
31 Dec 22128-314161193
30 Sep 22137-299153193
30 Jun 22140-206148173
31 Mar 22135-175138145
31 Dec 21131-181124113
30 Sep 21122-3710588
30 Jun 21106-779477
31 Mar 2192-598069
31 Dec 2079297364
30 Sep 2080-468461
30 Jun 2083-517159
31 Mar 2090-537559
31 Dec 1991-847560
30 Sep 1982-1156262
30 Jun 1979-1116861
31 Mar 1976-1096462
31 Dec 1879-1036363
30 Sep 1884-935862
30 Jun 1889-905863
31 Mar 1888-935965
31 Dec 1793-925965
30 Sep 1794-905866
30 Jun 1796-865668
31 Mar 1797-795168
31 Dec 1691-744868
30 Sep 16101-574866
30 Jun 1690-374665
31 Mar 1694-314662
31 Dec 1593-324560
30 Sep 1573-494258
30 Jun 1580-604154
31 Mar 1567-674051
31 Dec 1461-663848
30 Sep 1453-643747
30 Jun 1440-763846
31 Mar 1434-773845
31 Dec 1328-793945
30 Sep 1325-844343
30 Jun 1320-864246
31 Mar 1322-884445

Quality Earnings: PACB is currently unprofitable.

Growing Profit Margin: PACB is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PACB is unprofitable, and losses have increased over the past 5 years at a rate of 36.2% per year.

Accelerating Growth: Unable to compare PACB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PACB is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-9.3%).


Return on Equity

High ROE: PACB has a negative Return on Equity (-43.74%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.